Preclinical studies consistently show GLP-1 receptor agonists reduce substance intake and relapse-like behavior across multiple addictions, though human evidence remains preliminary.
5+ substances targetedGLP-1 drugs reduce intake and relapse-like behavior for alcohol, nicotine, opioids, psychostimulants, and cannabinoids in preclinical models
What the researchers found
Preclinical studies consistently demonstrate GLP-1 RAs reduce substance intake, attenuate reward-related behaviors, and suppress relapse-like responding across alcohol, nicotine, opioids, psychostimulants, and cannabinoids.
Why it matters
Addiction is a leading cause of death and disability globally, with limited effective pharmacotherapies. GLP-1 drugs are already widely available and could represent a breakthrough treatment if addiction benefits are confirmed in clinical trials.
How the study worked
Narrative review of preclinical animal models and human observational studies on incretin-based therapies in addiction across multiple substance classes.
What this study cannot tell us
Human evidence is largely observational. No published randomized controlled trials for addiction specifically. Animal models may not fully predict human addiction responses. Long-term effects of GLP-1 drugs on brain reward circuits are unknown.
How to read the evidence
Strong preclinical evidence across multiple substance classes. Human evidence is preliminary and observational. Randomized controlled trials are needed.
When this study was published
Published in 2025, reviewing the rapidly growing field of incretin-based addiction therapy.
The bigger picture
The discovery that metabolic peptide signaling directly interacts with brain reward circuits has opened an entirely new therapeutic approach to addiction, bridging endocrinology and psychiatry in unprecedented ways.
Questions still open
- Will randomized controlled trials confirm GLP-1 drugs' efficacy for specific addictions?
- Which GLP-1 drug and dose would be optimal for addiction treatment?
- Are the anti-addiction effects mediated by peripheral metabolic changes or direct brain GLP-1 receptor activation?
Common questions
Can Ozempic or Wegovy help with addiction?
How might a diabetes drug help with addiction?
Read the original research
Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.
Journal of clinical medicine, 15(4)
Citation
Dawid, Rosiejka; Joanna, Michałowska; Justyna, Marcickiewicz; Bogdańska, Adela; Błażejewska, Wiktoria; Szulińska, Monika. (2026). Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.. Journal of clinical medicine, 15(4). https://doi.org/10.3390/jcm15041613